Interleukin-21: a critical regulator of the balance between effector and regulatory T-cell responses

Trends Immunol. 2008 Jun;29(6):290-4. doi: 10.1016/j.it.2008.02.008. Epub 2008 Apr 25.

Abstract

Naïve T cells can commit to effector [T helper 1 (Th1), Th2 and Th17] or regulatory lineages. Skewing of responses toward inflammatory Th1, Th2 or Th17 pathways and away from regulatory T-cell pathways might be responsible for the initiation and progress of immune-mediated diseases. Based on recent data, we propose that interleukin-21 (IL-21), a cytokine produced by activated CD4+ T cells, induces the development of Th17 cells, blocks the differentiation of transforming growth factor-beta1-induced regulatory T cells and renders CD4+ T cells resistant to the suppressive effects of regulatory T cells, thereby playing a major role in pathogenic T-cell responses.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antibody Formation / drug effects
  • B-Lymphocytes / immunology
  • B-Lymphocytes / metabolism
  • CD8-Positive T-Lymphocytes
  • Cell Differentiation / drug effects
  • Cell Differentiation / immunology
  • Cell Proliferation / drug effects
  • Humans
  • Immune System Diseases / therapy
  • Inflammation
  • Interleukins* / immunology
  • Interleukins* / metabolism
  • Interleukins* / pharmacology
  • Lymphocyte Activation / drug effects
  • Lymphocyte Activation / immunology*
  • Th1 Cells / immunology*
  • Th1 Cells / metabolism
  • Th2 Cells / immunology*
  • Th2 Cells / metabolism
  • Transforming Growth Factor beta1 / antagonists & inhibitors*

Substances

  • Interleukins
  • Transforming Growth Factor beta1
  • interleukin-21